Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of BG505 SOSIP.664 gp140 HIV vaccine with AS01B
PACTR202006565880683Phase 1Completed
- Sponsor
- International AIDS Vaccine Initiative
- Start
- Mar 2019
- Modality
- Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 1, single-arm trial of BG505 SOSIP.664 gp140 and AS01B in human immunodeficiency virus infection (HIV), sponsored by International AIDS Vaccine Initiative. Started Mar 2019; status: completed.
02
Drugs
BG505 SOSIP.664 gp140AS01B
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202006565880683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202006565880683.